Evidence map›Paper›PMID 22500684›Full record

ReviewExpert review of anticancer therapy2012

The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer.

Randall J Kimple, Suzanne Russo, Arta Monjazeb, A William Blackstock

Abstract readReview
In one paragraph

Review in Expert review of anticancer therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Randall J KimpleDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
Suzanne Russo
Arta Monjazeb
A William Blackstock

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
UC Davis Clinical and Translational Science CenterKL2RR024144 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2006 to 2011
$3.1M
Head and Neck squamous cell carcinoma radiation response modulation by HPVK99CA160639 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KIMPLE, RANDALL J. · 2011 to 2012
$298k
NCI NIH HHS K99 CA160639NCI NIH HHS K99 CA160639-01NCI NIH HHS P30 CA012197-36NCRR NIH HHS 2 KL2 RR024144-06NCRR NIH HHS KL2 RR024144
6 · The paper itself

Abstract

Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.

Indexed as

Combined Modality TherapyHumansPancreatic NeoplasmsSurvival Rate

Identifiers

PMID22500684
PMCPMC3628691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.